Given the published roles of PI3K/AKT/mTOR, and more recently of PIM kinase signalling in mediating resistance to HER2- targeted therapies [36], we evaluated IBL-302 in breast cancer models of acquired trastuzumab and lapatinib resistance. This evidence concerns the gene ERBB2 and breast cancer.